Kiniksa-2026-JPM.pdf

1、AnnaLiving with Recurrent PericarditisWere relentless and focused on putting patients at the center of everything we do as we strive to produce life-changing medicinesWho We AreJP Morgan ConferenceJANUARY 2026Every Second Counts2This presentation(together with any other statements or information tha

2、t we may make in connection herewith)contains forward-looking statements with respect to Kiniksa Pharmaceuticals International,plc(and its consolidated subsidiaries,collectively,unless context otherwise requires,“Kiniksa,”“we,”“us”or“our”).In some cases,you can identify forward looking statements by

3、 terms such as“may,”“will,”“should,”“expect,”“plan,”“anticipate,”“could,”“intend,”“goal,”“design,”“target,”“project,”“contemplate,”“believe,”“estimate,”“predict,”“potential,”“strategy,”or“continue”or the negative of these terms or other similar expressions,although not all forward-looking statements

4、 contain these identifying words.All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements,including without limitation,statements regarding our strategy;potential value drivers;potential indications;potential marke

5、t opportunities and competitive position,including statements that Kiniksa has established the recurrent pericarditis market with line of sight to future blockbuster status;ongoing,planned and potential clinical trials and other studies;timing and potential impact of clinical data;regulatory and oth

6、er submissions,applications and approvals;commercial strategy and commercial activities;expected run rate for our cash,cash equivalents and short-term investments;expected funding of our operating plan;financial guidance;and capital allocation.These forward-looking statements are based on management